September 2020


In May 2020, Rutgers Cancer Institute of New Jersey, the state’s only NCI-designated Comprehensive Cancer Center, became the 37th member of the Caris Precision Oncology Alliance™ (POA).  In partnership with RWJBarnabas Health, Rutgers Cancer Institute provides advanced cancer treatment for adults and children, including innovative clinical trials, immunotherapy, precision medicine, complex surgical procedures and sophisticated radiation therapy techniques. Rutgers Cancer Institute is also one of only two entities in New Jersey to provide bone marrow transplantation and CAR T-cell therapy.

From diagnosis through treatment and into survivorship Rutgers Cancer Institute also offers robust oncology support services for patients and their families.  As part of the multidisciplinary care team, oncology nurses play a critical role providing exceptional care to patients. The Institute’s oncology nurses are regular presenters at the Oncology Nursing Society Annual Congress where they share their knowledge and best practices with their peers from around the world.

As an NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute has 259 research members from Rutgers University and Princeton University who work together to accelerate cancer research and its translation to patient care. Rutgers Cancer Institute’s research enterprise includes a number of cancer-focused programs: Cancer Metabolism and Growth, Genomic Instability and Cancer Genetics, Cancer Pharmacology, Clinical Investigations and Precision Therapeutics, and Cancer Prevention and Control. These programs are supported in part by comprehensive shared resources, which include Biomedical Informatics, Genome Editing, Metabolomics Service, among others.

Rutgers Cancer Institute’s multi-disciplinary team of clinical specialists and renowned researchers work to advance our understanding of cancer; identify, develop and provide access to new cancer therapies; and educate the public about cancer prevention and screening.

Dr. Chadi Nabhan, Chairman of the POA, welcomes the recent addition of the Institute to the alliance, stating, “Caris looks forward to working with the Rutgers Cancer Institute of New Jersey and its team of internationally recognized physicians and researchers who have a proud legacy of transforming laboratory discoveries into clinical practice in furthering this mission.”

“We look forward to harnessing the valuable insights generated by the Precision Oncology Alliance and the opportunity to provide our own valuable contributions to the latest advancements in personalized medicine,” said Shridar Ganesan, M.D., Ph.D., Associate Director for Translational Science and Chief of Molecular Oncology at Rutgers Cancer Institute, who is also a Professor of Medicine and Pharmacology at Rutgers Robert Wood Johnson Medical School and the Omar Boraie Chair in Genomic Science.

For more information, please visit

Share to:

Rutgers Cancer Institute of NJ
RWJBarnabas Health
Rutgers Health
New Brunswick, NJ